RWE: From “Nice to Have” TO “Must Have”

Are you ready to meet healthcare stakeholders’ ever-increasing evidence demands?

White Paper

November 26, 2018
RWE From Nice To Have to Must Have
In this white paper, we will review the landscape of use cases for RWE among different healthcare stakeholders with a focus on Europe, while highlighting variations and limitations in RWE acceptance. We will further look at trends that are shaping this dynamic picture and how they might play out over the medium term. Finally, we will draw out implications for pharmaceutical companies of how to embrace this new world.